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Rho-associated kinase (Rho-kinase/ROCK/ROK) is an
effector of the small GTPase Rho and belongs to the AGC
family of kinases. Rho-kinase has pleiotropic functions
including the regulation of cellular contraction, motility,
morphology, polarity, cell division, and gene expression.
Pharmacological analyses have revealed that Rho-kinase is
involved in a wide range of diseases such as vasospasm, pul-
monary hypertension, nerve injury, and glaucoma, and is
therefore considered to be a potential therapeutic target.
This review focuses on the structure, function, and modes
of activation and action of Rho-kinase.




ho-kinase, originally identiﬁed as an effector of the
small GTPase Rho [Leung et al., 1995; Ishizaki et al.,
1996; Matsui et al., 1996], plays a major role in mediating
rearrangements of the actomyosin cytoskeleton downstream
of Rho. Rho family small GTPases, such as Rho, Rac, and
Cdc42, regulate cytoskeletal reorganization in different ways
[Kaibuchi et al., 1999; Jaffe and Hall, 2005]. The functions
of these GTPases have been primarily investigated with
regard to their effects of actin ﬁlaments. Rho regulates stress
ﬁber formation and cell contraction, whereas Rac and Cdc42
regulate the formation of lamellipodia and ﬁlopodia, respec-
tively, and promote protrusive activities [Hall, 2005]. Rho
family GTPases also modulate microtubule dynamics and
cell polarity. Furthermore, in addition to Rho-kinase, many
other Rho effectors with various functions have been identi-
ﬁed, including the myosin phosphatase-targeting subunit 1
(MYPT1) of myosin light chain (MLC) phosphatase, mDia,
Protein kinase N (PKN), Citron, Citron-kinase, Rhotekin,
and Rhophilin, and many act in concert following Rho acti-
vation. For example, Rho-kinase functions together with
MYPT1 and mDia to achieve stress ﬁber and focal adhesion
formation downstream of Rho [Amano et al., 2000; Naru-
miya et al., 2009]. In this review, we will focus on the struc-
ture, function, and modes of action of Rho-kinase.
Structure and Modes of Activation and
Inhibition
Domain structure
Rho-kinase is a serine/threonine kinase belonging to the AGC
family of protein kinases, which are structurally related to myo-
tonic dystrophy kinase (DMPK) and myotonic dystrophy
kinase-related CDC42-binding kinase (MRCK). There are two
Rho-kinase members, Rho-kinase a/ROCK2/ROKa and Rho-
kinase b/ROCK1/ROKb: we will refer to them collectively as
Rho-kinase. Rho-kinase is composed of an N-terminal catalytic
domain, a central coiled-coil domain, and a C-terminal PH do-
main interrupted by a Cys-rich region (Fig. 1). Rho-kinase
requires both N- and C-terminal extension segments in addition
to the core catalytic domain for its activity, which is conserved
among the DMPK subgroup (see below). Rho activates Rho-ki-
nase by binding to the C-terminal portion of the coiled-coil.
Crystal structure
Unique features of the Rho-kinase catalytic domain have been
revealed by studies of its crystal structures. Rho-kinase has N-
and C-terminal extension segments outside the catalytic do-
main that form an intermolecular head-to-head homodimer,
keeping it in an active conformation [Yamaguchi et al., 2006a;
Jacobs et al., 2006] (Fig. 2). Interestingly, phosphorylation at
the activation loop or C-terminal hydrophobic motif, which is
necessary for most of other AGC kinases such as PKC and
Akt, is absent from the Rho-kinase catalytic domain in its
dimerized active conformation [Yamaguchi et al., 2006a]. The
Rho-binding region of Rho-kinase also forms a parallel coiled-
coil structure [Shimizu et al., 2003; Dvorsky et al., 2004], sup-
porting the idea that Rho-kinase dimerizes in a parallel
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545 nmanner. Consistent with this, Rho-kinase is found as a multi-
mer in the cell [Chen et al., 2002].
Activation and inactivation
The C-terminal segment containing the Rho-binding and PH
domains acts as the negative regulatory region of Rho-kinase.
That the interaction between active Rho (Rho GTP) and the
Rho-binding domain releases this inhibition is based on several
lines of evidence: (1) deletion of the C-terminal portion results
in constitutive activation of Rho-kinase [Leung et al., 1996;
Amano et al., 1997; Ishizaki et al., 1997], (2) the C-terminal
segment interacts with and inhibits the constitutively active cata-
l y t i cf r a g m e n tb o t hi nv i t r oa n di nv i v o[ A m a n oe ta l . ,1 9 9 9 ] ,
and (3) an antibody against the Rho-binding domain of Rho-ki-
nase enhances its kinase activity in vitro (unpublished observa-
tion). In addition to Rho, certain lipids such as arachidonic acid
can activate Rho-kinase via its PH domain [Araki et al., 2001].
Proteolytic cleavage at the C-terminus by caspase-3 and gran-
zyme B is also reported to activate ROCK1 and ROCK2, lead-
ing to plasma membrane blebbing during apoptosis [Coleman
et al., 2001; Sebbagh et al., 2001; Sebbagh et al., 2005]. Other
small GTPases besides Rho - Rnd3/RhoE, Gem and Rad - can
bind Rho-kinase outside of the Rho-binding region and inhibit
its function [Ward et al., 2002; Riento et al., 2003; Komander
et al., 2008]. It has also been reported that PDK1 directly binds
to ROCK1 in competition with RhoE, leading to the release of
ROCK1 from RhoE and activation [Pinner and Sahai, 2008].
ROCK1 and ROCK2
The structures of ROCK1 and ROCK2 are conserved with
64% overall amino acid identity (Fig. 1). The kinase domain
containing both extension segments is more highly conserved
between these two proteins (83% identical), suggesting that
they may have similar substrate speciﬁcity. The consensus
Fig. 1. Structure of Rho-kinase/ROCK/ROK. Schematic diagrams of the domain structure of Rho-kinases. Amino acid sequence identities
for each domain are indicated.
Fig. 2. Ribbon diagram of the dimmer structure of catalytic domain of Rho-kinase. Rho-kinase forms a head-to head homodimer
through its N- and C-terminal extensions. Fasudil binds to the ATP-binding cleft. Predicted whole structure of Rho-kinase is also shown, in
which Rho-kinase forms parallel dimmer through both the extensions outside of catalytic domain and central coiled-coil regions. Arrows
indicate the active centers of Rho-kinase. Reprinted from Structure, Vol 14(3), 2006, Yamaguchi et al., DOI: 10.1016/j.str.2005.11.024;
V C2005, with permission from Elsevier.
n 546 Amano et al. CYTOSKELETONphosphorylation sequence for Rho-kinase is R/KXS/T or
R/KXXS/T (X is any amino acid). Both Rho-kinase proteins
are ubiquitously expressed in most tissues; however, higher
levels of ROCK2 are found in brain and muscles whereas
higher levels of ROCK1 are found in non-neuronal tissues
including liver, lung and testis [Leung et al., 1996; Naka-
gawa et al., 1996]. So far, several functional differences
between ROCK1 and ROCK2 have been reported. ROCK1
is speciﬁcally cleaved by caspase-3, whereas ROCK2 is
cleaved by granzyme B [Coleman et al., 2001; Sebbagh
et al., 2001; Sebbagh et al., 2005]. RhoE preferentially binds
ROCK1, but not ROCK2, whereas MYPT1 binds only
ROCK2 [Komander et al., 2008; Wang et al, 2009]. Gene
silencing experiments also suggest different cellular functions
for these two proteins, ROCK1 appears to be essential for
the formation of stress ﬁbers, whereas ROCK2 appears to be
necessary for phagocytosis and cell contraction, both of
which are dependent on MLC phosphorylation [Yoneda
et al., 2005; Wang et al., 2009]. Most if not all mice carry-
ing a homozygous deletion of the either the ROCK2 or
ROCK1 allele show embryonic or postnatal lethality, respec-
tively, whereas heterozygous mice are fertile and appear nor-
mal [Thumkeo et al., 2003; Shimizu et al., 2005; Thumkeo
et al., 2005]. However, the question of whether these two
Rho-kinase proteins are qualitatively different or expressed at
different abundances in tissues remains unanswered.
Inhibitors
To elucidate the physiological roles of Rho-kinase, small mole-
cule inhibitors have been developed and investigated in various
cell types and animal models [Mueller et al., 2005; Shimokawa
and Rashid, 2007]. Fasudil (HA-1077) and Y-27632 have
been broadly used as Rho-kinase selective inhibitors and func-
tion in an ATP-competitive manner. Fasudil, composed of the
isoquinoline ring and the pendant ring of the seven-membered
homopiperazine, is used clinically for cerebral vasospasm after
subarachnoid hemorrhage in Japan. H-1152 has been devel-
oped by optimization of a series of isoquinoline compounds.
Y-27632 was identiﬁed by its ability to inhibit phenylephrine-
induced contraction of a rabbit aortic strip and contains a 4-
aminopyridine ring [Uehata et al., 1997]. Structural analyses
of the Rho-kinase (ROCK2)-Fasudil complex [Yamaguchi
et al., 2006a], Rho-kinase (ROCK2)-Y-27632 complex [Yama-
guchi et al., 2006b], and ROCK1-Y-27632 complex [Jacobs
et al., 2006] revealed the inhibitors cause an induced-ﬁt con-
formational change to increase contacts with Rho-kinase phos-
phate loop, which may account for their speciﬁcity. Several
pharmaceutical companies are investing in the development of
Rho-kinase inhibitors for the treatment of certain diseases,
such as glaucoma (see [Hahmann and Schroeter, 2010] for a
review). Notably, the ROCK2-selective inhibitor SLx-2119
[Boerma et al., 2008] is now in clinical trials.
Functions
Rho-kinase members play roles in various cellular functions
through phosphorylation of their speciﬁc substrates (Fig. 3
and Table I)
Cell contraction and actin organization
Smooth muscle contraction. Vascular smooth muscle
tone is regulated by MLC phosphorylation of myosin II,
Fig. 3. Substrates of Rho-kinase. Rho-kinase inhibits the MLC phosphatase activity through both phosphorylation of MYPT1 of MLC
phosphatase and phosphorylation of CPI17, an inhibitory protein of myosin phosphatase. Rho-kinase and MLC phosphatase share their sub-
strates, such as MLC, ERM proteins, adducin and MAPs, and thought to regulate the level of phosphorylation. The substrates reported to
be phosphorylated by Rho-kinase are illustrated; actin-bindig/regulating proeins (red), MT-binding/regulating proteins (blue), intermediate
filaments (yellow), and proteins in other signaling pathways (green). Physiological (black) and pathological (red) processes in which Rho-ki-
nase is involved are listed at the bottom right.
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2þ-dependent MLC kinase and MLC
phosphatase. The Rho/Rho-kinase signaling pathway is known
to modulate the ‘‘Ca
2þ-sensitivity’’ of smooth muscle mainly
through the suppression of MLC phosphatase activity. MLC
phosphatase is composed of the catalytic subunit (PP1cd) and
two regulatory subunits, myosin phosphatase-targeting subunit
1 (MYPT1) and M20 [Ito et al., 2004]. Rho-kinase phospho-
rylates MYPT1 at two inhibitory sites, Thr853 and Thr696,
resulting in a decrease in MLC phosphatase activity and
an increase in phosphorylated MLC [Kimura et al., 1996].
Rho-kinase can also phosphorylate MLC at Ser19 to increases
myosin ATPase activity at least in vitro [Amano et al., 1996],
although a direct contribution of Rho-kinase to phospho-
MLC levels in vivo is not yet proved. CPI-17 has an inhibitory
effect on MLC phosphatase when it is phosphorylated by PKC
at Thr38 and is also reported to be phosphorylated by Rho-
Table I. List of Known Substrates and Effects of Phosphorylation
Substrate Effect of phosphorylation Cellular function Reference
Microﬁlament
MYPT1 Inhibition of MLC phosphatase Increase in cell contraction [Kimura et al., 1996]
MLC Activation of myosin ATPase Increase in cell contraction [Amano et al., 1996]
ERM Maintenance of crosslinking Microvilli formation? [Fukata et al., 1998]
[Oshiro et al., 1998]
[Matsui et al., 1998]
Adducin Enhancement of F-actin binding Cell migration [Fukata et al., 1999]
LIMK1/2 Activation of coﬁlin phosphorylation Stress ﬁber formation [Maekawa et al., 1999]
[Ohashi et al., 2000]
Calponin Inhibition of F-actin binding n.d. [Kaneko et al., 2000]
CPI-17 Inhibition of MLC phosphatase Increase in cell contraction [Koyama et al., 2000]
NHE1 n.d. Stress ﬁber formation [Tominaga and Barber, 1998]
[Denker et al., 2000]
MARCKS Inhibition of F-actin binding n.d. [Nagumo et al., 2001]
EF1a Inhibition of F-actin binding n.d. [Izawa et al., 2000]
Troponin I/T n.d. Inhibition of Ca2þ response
in cardiac muscle
[Vahebi et al., 2005]
Proﬁlin Inhibition of G-actin binding Decrease in polyQ aggregation [Shao et al., 2008]
[Bauer et al., 2009]
Microtubule
MAP2/Tau Inhibition of tubulin polymerization Inhibition of neurite elongation? [Amano et al., 2003]
CRMP2 Inhibition of tubulin polymerization Growth cone collapse [Arimura et al., 2000;
Arimura et al., 2005]
Doublecortin Inhibition of microtubule bundling Neuronal migration? [Amano et al., 2010]
Intermediate ﬁlament
GFAP Depolymerization Progression of cytokinesis [Yasui et al., 1998]
Vimentin Depolymerization Progression of cytokinesis [Goto et al., 1998]
Neuroﬁlament (NF-L) Depolymerization Neurite retraction [Hashimoto et al., 1998]
Signaling crosstalk
Par3 Dissociation of Par3/Tiam1
from Par6/aPKC
Control of cell migration [Nakayama et al., 2008]
STEF Inhibition of GEF activity? Inhibition of neurite outgrowth? [Takefuji et al., 2007]
p190RhoGAP Inhibition of Rnd binding Positive feedback signal of Rho? [Mori et al., 2009]
eNOS Inactivation of eNOS Cell contraction? [Sugimoto et al., 2007]
PTEN Activation of phosphatase activity? Cell polarity? [Li et al., 2005]
FilGAP Activation of RacGAP activity Lamella formation, cell polarity [Ohta et al., 2006]
IRS1 Positive/negative regulation
of insulin signal?
[Furukawa et al., 2005]
Endophilin Inhibition of CIN85 binding Inhibition of EGFR endocytosis [Kaneko et al., 2005]
P300 Increase in acetyltransferase activity Enhancement of transcription [Tanaka et al., 2006]
RhoE Stabilization Decrease of stress ﬁbers [Komander et al., 2008;
Riento et al., 2003]
n.d.: not deﬁned.
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2000]. Several studies using permeabilized smooth muscle and
selective inhibitors have shown that Rho-kinase activity is
involved in the modulation of smooth muscle tone, especially
during aberrant vascular contractions, such as coronary vaso-
spasm, cerebral vasospasm after subarachnoid hemorrhage,
and pulmonary hypertension [Shimokawa and Rashid, 2007].
Recently, we found that Rho-kinase phosphorylates p190Rho-
GAP, one of the major negative regulators of Rho, and pre-
sumably inhibits its GAP activity in smooth muscle cells [Mori
et al., 2009], which may form a positive feedback loop that
accounts for the hyperactivation of Rho at spastic sites.
Stress ﬁber formation. Stress ﬁbers and focal adhesions
confer contractility on a cell and are mediated by Rho/Rho-
kinase signaling pathway [Amano et al., 1997]. MLC phos-
phorylation which is necessary for the formation and mainte-
nance of stress ﬁbers and focal adhesions, is regulated by
Rho-kinase and MLC phosphatase downstream of Rho, in
cooperation with the Rho effector mDia [Watanabe et al.,
1999]. LIM kinases 1 and 2 are phosphorylated by Rho-ki-
nase at Thr508 and Thr505, respectively, resulting in
increased coﬁlin phosphorylation at Ser3 [Maekawa et al.,
1999]. Coﬁlin is an actin-depolymerizing factor and regulates
actin dynamics, and its activity is inhibited by phosphoryla-
tion. Rho-kinase seems to induce and maintain stress ﬁbers
by increasing contractility via MLC phosphorylation and by
stabilizing actin ﬁlaments through LIMK activation which
results in coﬁlin phosphorylation. Isolated contractile stress
ﬁbers from ﬁbroblasts contain Rho, Rho-kinase and MYPT1,
and their contraction is sensitive to Rho-kinase inhibitors
[Katoh et al., 2001], suggesting that Rho, Rho-kinase and
MLC phosphatase associate with microﬁlaments to form a
modulatory apparatus for acto-myosin contraction.
Cell migration
Mode of cell migration. Multiple events are coordin-
ately regulated during cell migration: polarization in the
direction of movement, reorganization of the cytoskeleton,
turnover of membranes, and remodeling of cell adhesions.
Cell-to-cell and cell-to-substratum interactions are important
for cell migration. Proper cell movement is essential for de-
velopment, wound healing and inﬂammation. Aberrant cell
migration may lead to increased tumor cell invasion and ar-
teriosclerosis. Rho family GTPases play critical roles in regu-
lation of cell migration through their speciﬁc effectors
[Etienne-Manneville and Hall, 2002; Fukata et al., 2003].
The roles of Rho/Rho-kinase in cell migration depend on
the cell type and mode of migration [Nakayama et al.,
2005]. Inhibition of Rho or Rho-kinase results in the inhibi-
tion of migration through Boyden chambers, but not attach-
ment, of monocytes [Worthylake et al., 2001], neutrophils,
HL-60 [Hauert et al., 2002], eosinophils [Alblas et al.,
2001], and smooth muscle cells [Ai et al., 2001; Nishiguchi
et al., 2003]. Monocytes treated with Y-27632 or C3 exoen-
zyme (an inhibitor of Rho) have elongated tails, and cause a
defect in tail detachment, and a mislocalizated integrins, the
latter of which is not observed in cells treated with myosin
inhibitors [Worthylake et al., 2001]. This suggests that not
only myosin-mediated contraction but also integrin reorgan-
ization is necessary for the Rho/Rho-kinase-mediated tail re-
traction. Rho or Rho-kinase inhibitors also affect the
chemokinesis of neutrophils and HL-60 cells. fNLPNTL-
induced neutrophil polarization is inhibited to some extent
by treatment with Y-27632, whereas the number of non-po-
lar cells with rufﬂes is increased [Hauert et al., 2002]. Simi-
lar results have been shown for HL-60 cells stimulated with
fMLP - the number of cells with ﬂattened morphologies and
multiple pseudopods is increased by the inhibition of Rho,
Rho-kinase or myosin II [Xu et al., 2003]. In Y-27632-
treated HL-60 cells, the level of activated Rac is increased af-
ter stimulation with fMLP, suggesting that the multiple pseu-
dopods observed after the inhibition of Rho/Rho-kinase are
the consequence of aberrant activation of Rac. The migration
of ﬁbroblasts during wound healing or random migration is
not inhibited, but rather enhanced, by inhibition of Rho or
Rho-kinase [Nobes and Hall, 1999; Magdalena et al., 2003;
Totsukawa et al., 2004]. In contrast to neutrorphils and HL-
60 cells, Rho-kinase inhibition by Y-27632 leads to faster
and straighter migration with a single leading edge and with-
out Rac activation, whereas MLCK inhibition results in the
formation of multiple protrusions in gerbil ﬁbroma cells
[Totsukawa et al., 2004].
Furthermore, it has been shown that tumor cells use at
least two types of migration in a three-dimensional matrix:
Rho/Rho-kinase-dependent and Rac-dependent migration
[Sahai and Marshall, 2003]. Several tumor cell lines, such as
A375 melanoma cell lines, can migrate through a 3D matrix
in a Rac-dependent mesenchymal fashion or in a Rho/Rho-
kinase-dependent amoeboid fashion. Inhibition of Rho-kinase
converts their morphology from amoeboid to mesenchymal in
a DOCK3 (RacGEF)/Rac/WAVE2-dependent manner, whereas
silencing of DOCK3 or Rac1 converts cells from the mesenchy-
mal morphology to amoeboid one in a Rho-kinase/ARH-
GAP22 (RacGAP)-dependent manner, suggesting that these
two types of migration are interconvertible and antagonistic
[Sanz-Moreno et al., 2008].
Front-rear polarity. The establishment of front-rear po-
larity is another important process for efﬁcient cell migra-
tion. Various molecules and/or activation states of proteins
are distributed asymmetrically in the polarized cell. Rho-ki-
nase inhibitors impair cell polarization, leading to random
protrusions and multiple leading edges in certain cell types.
This suggests that Rho-kinase is necessary for breaking sym-
metry and/or maintaining the polarized imbalance, by sup-
pressing extension of membrane except at the front leading
edge. In neutrophils, PTEN is localized at the rear of cell
and suppresses the production of PI(3,4,5)P3; the distribu-
tion of PTEN is under the control of Rho/Rho-kinase, most
likely by the phosphorylation of PTEN by Rho-kinase [Li
et al., 2005]. We recently showed that Rho-kinase also phos-
phorylates PAR-3, a component of the PAR polarity
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PAR-6/aPKC complex [Nakayama et al., 2008]. Because
PAR-3 binds to the Rac GEF Tiam1/Tiam2 (STEF) and
aPKC stimulates Rac GEF activity, Rho-kinase indirectly
abrogates Rac activation by phosphorylating PAR-3. PAR-3
phosphorylation by Rho-kinase is observed not only at the
rear of the cell but also at the leading edge, which may
reﬂect the role of Rho-kinase in modulating the extent of
protrusions by counteracting Rac activity.
Neurite elongation and neuronal architecture
Growth cone collapse. Rho and Rho-kinase are highly
expressed in the nervous system, implying important roles
for these proteins in neuron and/or glial cells. Several neu-
ron-speciﬁc substrates for Rho-kinase have been identiﬁed.
Collapsin response mediator protein 2 (CRMP-2) is abun-
dant in brain tissue, and is implicated in growth cone col-
lapse and neuronal polarization through its interaction with
tubulin heterodimers, numb, kinesin-1, and Sra-1. CRMP-2
is phosphorylated by Rho-kinase at Thr555, which impairs
its ability to bind to tubulin and numb [Arimura et al.,
2005]. Phosphorylation of CRMP-2 is increased by stimula-
tion with LPA and ephrin-A5 in DRG and hippocampal
neurons, respectively, and is implicated in growth cone col-
lapse induced by these repulsive cues [Arimura et al., 2000;
Arimura et al., 2005]. MAP2, Tau, and neuroﬁlament are
also neuron-speciﬁc substrates for Rho-kinase, and their
microtubule polymerizing activity and neuroﬁlament assem-
bly are inhibited by phosphorylation by Rho-kinase [Hashi-
moto et al., 1998; Amano et al., 2003]. Phosphorylation of
MAP2/Tau and neuroﬁlament may prevent neurite elonga-
tion and shorten neurites by destabilizing microtubules and
intermediate ﬁlaments. The control of cellular contraction
through MYPT1/MLC phosphorylation by Rho-kinase is
also thought to participate in neurite retraction and inhibi-
tion of neurite outgrowth [Amano et al., 1998; Hirose et al.,
1998]. LIMK1/coﬁlin has also been implicated in regulation
of growth cone morphology in chick DRG neurons [Endo
et al., 2003], potentially downstream of Rho-kinase.
Neuronal architecture and neurite elongation. Phar-
macological studies have revealed many roles for Rho-kinase
in the nervous system. Treatment of cultured cerebellar gran-
ule neurons with Y-27632 triggered immediate neurite out-
growth at an early stage, though it was less effective at later
stages, suggesting that Rho-kinase controls the initiation of
axonogenesis [Bito et al., 2000]. At the neuronal maturation
stage, dendritic branching and spine formation are markedly
inhibited when constitutively activated RhoA is expressed in
hippocampal slice cultures; this effect can be abrogated by
the administration of Y-27632 [Nakayama et al., 2000],
implying that Rho-kinase plays a role in dendrite formation.
Rho-kinase inhibitors have also been shown to be effective
for treatment of some neurological disorders, including spi-
nal cord injury and Alzheimer’s disease [Mueller et al.,
2005]. Several myelin-derived proteins are known to prevent
axon regeneration after axon damage in the central nervous
system. Myelin-associated inhibitors, such as Myelin-associ-
ated glycoprotein (MAG), Nogo, and oligodendrocyte mye-
lin glycoprotein (OMgp) activate Rho through the p75
receptor in complex with co-receptors, and Rho-kinase inhib-
itors abolish myelin-associated inhibitor-induced repellant
effects in both cultured neuron and animal models [Mueller
et al., 2005]. One of the potential downstream effectors of
Rho-kinase in these signaling pathways is CRMP-2. CRMP-
2 is phosphorylated at Thr555 following treatment with
MAG or Nogo, and overexpression of CRMP-2 causes neurite
extension in the presence of MAG [Mimura et al., 2006].
Rho-kinase inhibitors also show a potential protective
effects in Alzheimer’s disease [Tang and Liou, 2007]. Alzhei-
mer’s disease is characterized by extracellular amyloid aggre-
gates of toxic 40- or 42-amino-acid long amyloid-b (Ab40
or Ab42) peptides, which are generated from amyloid pre-
cursor protein (APP) that is abnormally cleaved by a- and c-
secretases. Treatment with Y-27632 decreased the production
of Ab42 in SH-SY5Y cells expressing mutant APP (APPswe)
and in model mice [Zhou et al., 2003]. Shedding of APP,
which determines the alternative forms, soluble APP (sAPP)
and toxic Ab42, was also found to be modulated by Rho-ki-
nase in APPswe-expressing N2a cells [Pedrini et al., 2005].
Cytokinesis
Drastic reorganization of the cytoskeleton occurs during cell
division. During cytokinesis, cells are divided into two
daughter cells via an actomyosin-based contractile apparatus
known as the contractile ring to which Rho and Rho-kinase
are recruited. In addition to Rho, Plk1 has also been found
to associate with and activate Rho-kinase synergistically with
Rho during cytokinesis [Lowery et al., 2007]. Rho and Rho-
kinase are involved in both the progression of the cleavage
furrow formation and the disassembly of intermediate ﬁla-
ments beneath cleavage furrow [Matsumura, 2005] [Izawa
and Inagaki, 2006]. Rho-kinase regulates MLC phosphoryla-
tion through MLC phosphatase, and possibly by direct
phosphorylation, at the contractile ring. At the same time,
Rho-kinase phosphorylates the head domain of intermediate
ﬁlaments, such as vimentin, leading to the disassembly of
ﬁlaments that ensures furrow completion. Inhibition of
Rho-kinase by Y-27632 does not completely arrest cytokine-
sis in cultured cells, though it does induce some abnormalites
and delays in cleavage [Kosako et al., 2000]. Various other
kinases, such as Aurora-B and Citron-kinase, seem to play
redundant roles in cytokinesis.
Other functions
Ezrin/radixin/moesin (ERM) proteins were originally identi-
ﬁed as Rho-kinase substrates that are phosphorylated at
Thr567, Thr564, and Thr558, respectively; phosphorylation
of ERM proteins by Rho-kinase maintains their activity by
crosslinking transmembrane proteins to F-actin [Fukata
et al., 1998; Matsui et al., 1998]. PKC and MRCK were
also demonstrated to phosphorylate ERM at these sites, and
n 550 Amano et al. CYTOSKELETONthe contribution of Rho-kinase to ERM phosphorylation is
thought to depend on the cell type and situation, such as in
smooth muscle cells upon static pressure [Onoue et al.,
2008], in hippocampal neurons upon glutamate stimulation
[Jeon et al., 2002], in T cells from systemic lupus erythema-
tosus patients [Li et al., 2007], and in Jurkat cells upon Fas
ligand stimulation [Hebert et al., 2008].
Rho-kinase is also localized in the nucleus and interacts
with p300 acetyltransferase, which forms a large nuclear pro-
tein complex [Tanaka et al., 2006]. Rho-kinase phosphoryl-
ates p300 and activates its acetyltransferase activity, in vitro
and in vivo, resulting in the enhancement of p300-depend-
ent transcription in U205 cells [Tanaka et al., 2006].
Many genetic and pharmacological studies have implicated
Rho-kinase in various cellular functions in which the key
substrates remain obscure. Rho/Rho-kinase has been demon-
strated to be involved in planar polarity establishment down-
stream of the Wnt/Frizzled/Dishevelled pathway in
Drosophila eye and wing development [Winter et al., 2001]
and in zebraﬁsh gastrulation convergence and extension
[Marlow et al., 2002]. Nucleophosmin (NPM)/B23 is a cen-
trosomal protein that is reported to associate with Rho-ki-
nase at the centrosome [Ma et al., 2006]. NPM activates
Rho-kinase in a phosphorylation state-dependent manner by
CDK2/cyclin E, which is involved in preventing centrosome
reduplication [Ma et al., 2006]. Several lines of evidence sug-
gest that the Rho-kinase signaling pathway also modulates
cell survival and apoptosis, as Rho-kinase is known to be
involved in morphological changes that occur during apopto-
sis [Coleman et al., 2001; Sebbagh et al., 2001; Sebbagh
et al., 2005]. Recently, Rho-kinase inhibitors such as Y-
27632 have been shown to have protective effects on human
embryonic stem cells. Administration of Y-27632 prevents
apoptosis and enhances survival of human embryonic stem
cells at low culture density [Watanabe et al., 2007], possibly
through the regulation of MLC phosphorylation and cell-cell
interactions [Harb et al., 2008]. However, inhibition of Rho-
kinase activity can promote apoptosis in certain situations
[Shibata et al., 2003; Svoboda et al., 2004; Moore et al.,
2004] and enhances cytotoxic polyglutamate (polyQ) aggre-
gates of huntingtin, androgen receptor, ataxin-2, and atro-
pin-1 [Shao et al., 2008; Bauer et al., 2009].
Future Directions
Intensive studies of Rho and Rho-kinase have revealed their
importance in diverse cellular processes and pathologies,
paticularly in cultured cell lines, the cardiovascular system,
and the nervous system. One of the critical roles of Rho-ki-
nase is modulation of cellular contractility, and aberrant acti-
vation of Rho-kinase appears to be involved in some
cardiovascular and neurological diseases. However, the func-
tions of Rho-kinase in other tissues still remain largely
unsolved, despite its nearly ubiquitous expression in the
body. The generation and study of conditional knock-out
and knock-in mice of two family members of Rho-kinase
would provide important insight into their physioogical
roles. Furthermore, a comprehensive identiﬁcation of Rho-ki-
nase substrates is necessary for better understanding of Rho-
kinase signaling networks. We have recently identiﬁed more
than 100 potential substrates of Rho-kinase by the interac-
tome approach, using the catalytic domain of Rho-kinase,
and have isolated novel substrates such as Doublecortin,
AP180 and APP [Amano et al., 2010]. Rho-kinase contrib-
utes to complicated intracellular signaling networks in a wide
range of situations, and further analysis will shed light on its
biological mechanisms and potential therapeutics for the dis-
ease treatment.
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